Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MorphoSys and Daiichi Sankyo expand collaboration with two new cancer-related antibody program
June 2009
SHARING OPTIONS:

MUNICH, GermanyŚMorphoSys AG announced in May the next phase of its ongoing, oncology-focused therapeutic antibody collaboration with Daiichi Sankyo Co.
 
By exercising two options available under the parties' existing agreement, Daiichi Sankyo has selected two new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL technology. Daiichi Sankyo will carry out preclinical and clinical development and has worldwide marketing rights for all resulting products.
 
MorphoSys receives exclusive license fees and stands to receive milestones and royalties for the therapeutic antibody programs, as per the terms of the companies' existing agreement. Further financial details were not disclosed.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.